# Cell Tech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cell-tech

- Industry: Biotechnology
- Headquarters: Tianjin, China
- Total disclosed funding: $1.6M
- Latest round: Angel (Sep 29, 2015)
- Investors on record: 4

## About

Based in Tianjin, China, and established in 2015, Cell Tech is a biotechnology company that focuses on research in the field of cell therapy. Donghui Jing, the founder and CEO of the company, has a Ph.D. from the State University of New York, and has worked for Merck Millipore, Novartis, and other U.S. pharmaceutical companies. In September 2015, Cell Tech raised an angel funding for CNY 10 million in angel funding from new investors Manzi Venture Capital, Xiaochang Shuimu Investment, VenturesLab, and T-rex capital.

Cell Tech's main business is the research and development of cancer immune cell therapy. It uses genetically modified, patient's immune T-cells to fight and treat cancer. Its products can be categorized into 2 series, which are CAR-T classic products and hematological oncology CAR molecules. Products can be used for the treatment of acute lymphoblastic leukemia, non-Hodgkin's lymphoma, B-cell malignant tumors, and other diseases.

## Funding rounds

- Angel, Sep 29, 2015, $1.6M — VenturesLab, Xiaochang Shuimu Investment, Manzi Venture Capital, T-rex capital

## Investors

- VenturesLab — Angel
- Xiaochang Shuimu Investment — Angel
- Manzi Venture Capital — Angel
- T-rex capital (https://capitalatlas.ai/funds/t-rex-capital) — Angel